U.S. flag

An official website of the United States government


Send to:

Choose Destination

Carcinoid tumor

MedGen UID:
Concept ID:
Neoplastic Process
Synonym: Carcinoid tumor (disease)
SNOMED CT: Carcinoid tumor (443492008); Carcinoid tumor (189607006); Carcinoid tumor - morphology (189607006)
HPO: HP:0100570
Monarch Initiative: MONDO:0005369


A tumor formed from the endocrine (argentaffin) cells of the mucosal lining of a variety of organs including the stomach and intestine. These cells are from neuroectodermal origin. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVCarcinoid tumor

Conditions with this feature

Multiple endocrine neoplasia, type 1
MedGen UID:
Concept ID:
Neoplastic Process
Multiple endocrine neoplasia type 1 (MEN1) includes varying combinations of more than 20 endocrine and non-endocrine tumors. Endocrine tumors become evident either by overproduction of hormones by the tumor or by growth of the tumor itself. Parathyroid tumors are the most common MEN1-associated endocrinopathy; onset in 90% of individuals is between ages 20 and 25 years with hypercalcemia evident by age 50 years; hypercalcemia causes lethargy, depression, confusion, anorexia, constipation, nausea, vomiting, diuresis, dehydration, hypercalciuria, kidney stones, increased bone resorption/fracture risk, hypertension, and shortened QT interval. Pituitary tumors include prolactinoma (the most common), which manifests as oligomenorrhea/amenorrhea and galactorrhea in females and sexual dysfunction in males. Well-differentiated endocrine tumors of the gastro-entero-pancreatic (GEP) tract can manifest as Zollinger-Ellison syndrome (gastrinoma); hypoglycemia (insulinoma); hyperglycemia, anorexia, glossitis, anemia, diarrhea, venous thrombosis, and skin rash (glucagonoma); and watery diarrhea, hypokalemia, and achlorhydria syndrome (vasoactive intestinal peptide [VIP]-secreting tumor). Carcinoid tumors are non-hormone-secreting and can manifest as a large mass after age 50 years. Adrenocortical tumors can be associated with primary hypercortisolism or hyperaldosteronism. Non-endocrine tumors include facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas, and leiomyomas.
Neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome
MedGen UID:
Concept ID:
Disease or Syndrome
Multiple endocrine neoplasia type 4
MedGen UID:
Concept ID:
Neoplastic Process
Multiple endocrine neoplasia is a group of disorders that affect the body's network of hormone-producing glands called the endocrine system. Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia typically involves tumors (neoplasia) in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, the condition can be life-threatening.\n\nThe major forms of multiple endocrine neoplasia are called type 1, type 2, and type 4. These types are distinguished by the genes involved, the types of hormones made, and the characteristic signs and symptoms.\n\nMany different types of tumors are associated with multiple endocrine neoplasia. Type 1 frequently involves tumors of the parathyroid glands, the pituitary gland, and the pancreas. Tumors in these glands can lead to the overproduction of hormones. The most common sign of multiple endocrine neoplasia type 1 is overactivity of the parathyroid glands (hyperparathyroidism). Hyperparathyroidism disrupts the normal balance of calcium in the blood, which can lead to kidney stones, thinning of bones, nausea and vomiting, high blood pressure (hypertension), weakness, and fatigue.\n\nMultiple endocrine neoplasia type 4 appears to have signs and symptoms similar to those of type 1, although it is caused by mutations in a different gene. Hyperparathyroidism is the most common feature, followed by tumors of the pituitary gland, additional endocrine glands, and other organs.\n\nThe most common sign of multiple endocrine neoplasia type 2 is a form of thyroid cancer called medullary thyroid carcinoma. Some people with this disorder also develop a pheochromocytoma, which is an adrenal gland tumor that can cause dangerously high blood pressure. Multiple endocrine neoplasia type 2 is divided into three subtypes: type 2A, type 2B (formerly called type 3), and familial medullary thyroid carcinoma (FMTC). These subtypes differ in their characteristic signs and symptoms and risk of specific tumors; for example, hyperparathyroidism occurs only in type 2A, and medullary thyroid carcinoma is the only feature of FMTC. The signs and symptoms of multiple endocrine neoplasia type 2 are relatively consistent within any one family.

Professional guidelines


Collins ML, Okusanya O
Thorac Surg Clin 2023 May;33(2):159-164. Epub 2023 Feb 26 doi: 10.1016/j.thorsurg.2023.01.008. PMID: 37045485
Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D
Cancer Treat Rev 2016 Jun;47:32-45. Epub 2016 May 17 doi: 10.1016/j.ctrv.2016.05.003. PMID: 27236421
Korkmaz T, Seber S, Yavuzer D, Gumus M, Turhal NS
Crit Rev Oncol Hematol 2013 Sep;87(3):256-64. Epub 2013 Mar 9 doi: 10.1016/j.critrevonc.2013.02.003. PMID: 23478151

Recent clinical studies


Koehler K, Iams WT
Cancer Med 2023 Apr;12(7):7893-7903. Epub 2022 Dec 22 doi: 10.1002/cam4.5564. PMID: 36560885Free PMC Article
Rizen EN, Phan AT
Curr Oncol Rep 2022 Jun;24(6):703-714. Epub 2022 Mar 7 doi: 10.1007/s11912-022-01217-z. PMID: 35254612
Borczuk AC
Surg Pathol Clin 2020 Mar;13(1):35-55. Epub 2019 Nov 29 doi: 10.1016/j.path.2019.10.002. PMID: 32005434
Barakat MT, Meeran K, Bloom SR
Endocr Relat Cancer 2004 Mar;11(1):1-18. doi: 10.1677/erc.0.0110001. PMID: 15027882
Dawes L, Schulte WJ, Condon RE
Arch Surg 1984 Apr;119(4):375-8. doi: 10.1001/archsurg.1984.01390160011002. PMID: 6703893


Leikin JB
Dis Mon 2022 Jul;68(7):101303. Epub 2021 Dec 25 doi: 10.1016/j.disamonth.2021.101303. PMID: 34961605
Borczuk AC
Surg Pathol Clin 2020 Mar;13(1):35-55. Epub 2019 Nov 29 doi: 10.1016/j.path.2019.10.002. PMID: 32005434
Chowsanitphon J
Oncol Nurs Forum 2010 Nov;37(6):677-9. doi: 10.1188/10.ONF.677-679. PMID: 21059581
Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK
Lancet 1998 Sep 5;352(9130):799-805. doi: 10.1016/S0140-6736(98)02286-7. PMID: 9737302
Briselli M, Mark GJ, Grillo HC
Cancer 1978 Dec;42(6):2870-9. doi: 10.1002/1097-0142(197812)42:6<2870::aid-cncr2820420649>3.0.co;2-8. PMID: 365320


Cives M, Strosberg JR
CA Cancer J Clin 2018 Nov;68(6):471-487. Epub 2018 Oct 8 doi: 10.3322/caac.21493. PMID: 30295930
Mulkeen A, Cha C
Curr Opin Oncol 2005 Jan;17(1):1-6. doi: 10.1097/01.cco.0000147899.04701.c6. PMID: 15608504
Boushey RP, Dackiw AP
Curr Treat Options Oncol 2002 Aug;3(4):319-26. doi: 10.1007/s11864-002-0031-2. PMID: 12074768
Kinova S, Duris I
Bratisl Lek Listy 2001;102(11):495-504. PMID: 11901706
Lancet 1989 Sep 2;2(8662):541-2. PMID: 2570240


Rizen EN, Phan AT
Curr Oncol Rep 2022 Jun;24(6):703-714. Epub 2022 Mar 7 doi: 10.1007/s11912-022-01217-z. PMID: 35254612
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2021 Apr;32(4):439-451. Epub 2021 Jan 19 doi: 10.1016/j.annonc.2021.01.003. PMID: 33482246
McCarthy DM
Int J Mol Sci 2020 Jan 19;21(2) doi: 10.3390/ijms21020662. PMID: 31963924Free PMC Article
Pinchot SN, Holen K, Sippel RS, Chen H
Oncologist 2008 Dec;13(12):1255-69. Epub 2008 Dec 17 doi: 10.1634/theoncologist.2008-0207. PMID: 19091780Free PMC Article
Minardi AJ Jr, Zibari GB, Aultman DF, McMillan RW, McDonald JC
J Am Coll Surg 1998 Jun;186(6):664-8. doi: 10.1016/s1072-7515(98)00092-1. PMID: 9632155

Clinical prediction guides

Roncati L, Gasparri P, Gallo G, Bernardelli G, Zanelli G, Manenti A
Adv Exp Med Biol 2020;1226:87-95. doi: 10.1007/978-3-030-36214-0_7. PMID: 32030678
Wang AY, Ahmad NA
Curr Opin Gastroenterol 2006 Sep;22(5):529-35. doi: 10.1097/01.mog.0000239868.27328.1d. PMID: 16891885
Schnirer II, Yao JC, Ajani JA
Acta Oncol 2003;42(7):672-92. doi: 10.1080/02841860310010547. PMID: 14690153
Moertel CG
J Clin Oncol 1983 Nov;1(11):727-40. doi: 10.1200/JCO.1983.1.11.727. PMID: 6199469
Wood ER, Wood WG
South Med J 1980 May;73(5):621-6. doi: 10.1097/00007611-198005000-00021. PMID: 7375982

Recent systematic reviews

Villaescusa M, Andres MP, Amaral AC, Barbosa RN, Abrão MS
Minerva Obstet Gynecol 2021 Oct;73(5):606-613. Epub 2021 Apr 27 doi: 10.23736/S2724-606X.21.04792-4. PMID: 33904692
Reuling EMBP, Dickhoff C, Plaisier PW, Bonjer HJ, Daniels JMA
Lung Cancer 2019 Aug;134:85-95. Epub 2019 Apr 15 doi: 10.1016/j.lungcan.2019.04.016. PMID: 31320001
Njere I, Smith LL, Thurairasa D, Malik R, Jeffrey I, Okoye B, Sinha C
Pediatr Blood Cancer 2018 Aug;65(8):e27069. Epub 2018 May 10 doi: 10.1002/pbc.27069. PMID: 29745005
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants
Ann Oncol 2015 Aug;26(8):1604-20. Epub 2015 Feb 2 doi: 10.1093/annonc/mdv041. PMID: 25646366
Isidori AM, Lenzi A
Arq Bras Endocrinol Metabol 2007 Nov;51(8):1217-25. doi: 10.1590/s0004-27302007000800007. PMID: 18209859

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...